by | Sep 23, 2024 | Lupus Foundation of America, News & Events
Cullinan Therapeutics has filed an investigationalnew drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE). CLN-978 is an advanced, highly potent CD19 x CD3 bispecific T-cell engager...
by | Sep 21, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers investigated the prevalence of cardiovascular disease events (CVE) in people with systemic lupus erythematosus (SLE) looking at the risk based on sex, age, and race/ethnicity. Findings confirmed people with SLE have higher rates of CVE than...
by | Sep 20, 2024 | Lupus Foundation of America, News & Events
Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events, such as myocardial infarction (heart attack), stroke, and other thromboembolic events. Hydroxychloroquine (HCQ, known commercially as Plaquenil) is recommended for most...
by | Sep 16, 2024 | Lupus Foundation of America, News & Events
Autoimmune diseases, including systemic lupus erythematosus (SLE), are more common in women than men, and scientists are still trying to figure out why. One reason may be related to the number of X chromosomes a person has. Typically, females have two X chromosomes...
by | Sep 14, 2024 | Lupus Foundation of America, News & Events
A recent study found that regularly checking blood levels of hydroxychloroquine (HCQ, known commercially as Plaquenil®) may reduce the need for emergency room visits and hospitalizations for people living with lupus. HCQ is a widely used, safe medication for treating...
by | Sep 13, 2024 | Lupus Foundation of America, News & Events
Lupus can affect multiple parts of the body, including the eyes. Researchers looked at the case of a young woman who came to the hospital after experiencing sudden, painless vision loss in her right eye over two days. An ophthalmologist conducted a visual examination...
